Scarica l'app Stockscreener
35.63
0.45%
0.16
Dopo l'orario di chiusura:
35.39
-0.24
-0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$35.47
Aprire:
$35.95
Volume 24 ore:
2.77M
Relative Volume:
0.95
Capitalizzazione di mercato:
$4.12B
Reddito:
-
Utile/perdita netta:
$-359.64M
Rapporto P/E:
-11.19
EPS:
-3.1831
Flusso di cassa netto:
$-278.69M
1 W Prestazione:
+8.04%
1M Prestazione:
+22.86%
6M Prestazione:
+43.61%
1 anno Prestazione:
+19.85%
Intervallo 1D:
$35.25
$37.50
Intervallo di 1 settimana:
$32.51
$37.50
Portata 52W:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.63 | 4.12B | 0 | -359.64M | -278.69M | -3.1831 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity TrialsAnd What's Next - simplywall.st
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report? - Yahoo Finance
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap - Sahm
Is Viking Therapeutics (VKTX) Price Move Justified By DCF And Book Value Signals - Yahoo Finance
Why Has Viking Therapeutics (VKTX) Increased by 16.3% Since Its Previous Earnings Announcement? - Bitget
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026 - Meyka
Jefferies reiterates Buy on Viking Therapeutic stock, $101 target - Investing.com
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback? - NAI500
Net current asset value per share of Viking Therapeutics, Inc. – LS:A12GD6 - TradingView
WINTON GROUP Ltd Buys Shares of 68,700 Viking Therapeutics, Inc. $VKTX - MarketBeat
Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026 - The Motley Fool
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 - AOL.com
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - MSN
How Viking Therapeutics Inc. (VKTX) Affects Rotational Strategy Timing - Stock Traders Daily
Insider Buying: Neil Aubuchon Acquires Shares of Viking Therapeu - GuruFocus
Management Purchase Signals Confidence in Viking Therapeutics' Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Insider Acquires $149,912.50 in Stock - MarketBeat
Viking Therapeutics (VKTX) CCO buys 4,475 shares at $33.50 - Stock Titan
Viking Therapeutics Stock Gets RS Rating Upgrade - Investor's Business Daily
Viking Therapeutics at Leerink Conference: Strategic Moves in Obesity Market - Investing.com
2 Under-the-Radar Stocks to Buy and Hold - AOL.com
VKTX: Rapid progress in dual agonist obesity trials sets up major data and commercial milestones for 2026 - TradingView
VKTX: Phase 3 obesity trials advance rapidly, with pivotal data and new oral options expected in 2026 - TradingView
Viking Therapeutics (VKTX) Breaks Out From Multi-Year Down Trend - Bitget
Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in - Yahoo Finance
Top 10 Takeover Targets of 2026 - Genetic Engineering and Biotechnology News
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street - AOL.com
Viking Therapeutics, Inc. $VKTX Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Swings And Analyst Fair Value Gap - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Viking Therapeutics (VKTX) After Its Recent Share Price Swings - simplywall.st
Raymond James lowers Viking Therapeutics, Inc. (VKTX) price target amid optimistic clinical initiative outlook - MSN
Assessing Viking Therapeutics (VKTX) Valuation After Sharp Swings And Obesity Drug Optimism - simplywall.st
Viking Therapeutics, Inc. (VKTX) Experiences a Steeper Decline Compared to the Overall Market: Important Takeaways - Bitget
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - finance.yahoo.com
Notable Two Hundred Day Moving Average CrossVKTX - Nasdaq
Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play - Stocktwits
Biotech Viking Therapeutics heads to twin Miami investor conferences - Stock Titan
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):